Quince Therapeutics (formerly Cortexyme, Inc.; Nasdaq: QNCX) is a clinical-stage biotechnology company developing treatments for rare pulmonary diseases. Founded in 2012 as Cortexyme to pursue Alzheimer's therapies targeting the gingipain proteases of P. gingivalis, it rebranded as Quince in August 2022 after its lead program failed. After its eDSP program for ataxia-telangiectasia missed its Phase 3 primary endpoint, Quince acquired Orphai Therapeutics in May 2026 alongside a ~$115M private placement; its lead program is now LAM-001, an inhaled rapamycin in Phase 2 for bronchiolitis obliterans syndrome and planned for PH-ILD.
Cortexyme is publicly traded
IPO'd on May 9, 2019
This company is no longer available on our private secondary market. Shares can be traded publicly under CRTX.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2012
Total Funding
$101.7M
2 rounds
Quince Therapeutics (fka Cortexyme) to acquire Orphai Therapeutics via reverse merger with PIPE; Orphai team to take over management, pending stockholder vote.
Reverse merger dilutive for existing holders; liquidity hinges on vote outcome.
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $101.7M across 2 rounds
Last updated 10-05-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| May 2018 | Series B | $85.8M | — | Vulcan Capital |
| Jan 2016 | Series A | $15.9M | — | Pfizer Ventures |
Dirk Thye
Chief Executive Officer and Chief Medical Officer
Brigette Roberts
Chief Corporate Affairs Officer
Brendan Hannah
Chief Operating Officer and Chief Business Officer
David Lamond
Chairperson of the Board
Competitor list is illustrative and may be incomplete, stale, or erroneous.
IntraBio
Clinical-stage biotech developing therapies for rare neurological diseases including ataxia-telangiectasia and Niemann-Pick.
PTC Therapeutics
Rare disease biopharma with neurology focus; commercial and clinical programs in pediatric rare CNS disorders.
Stoke Therapeutics
Clinical-stage rare neurogenetic disease biotech developing antisense oligonucleotide therapies.
Ultragenyx Pharmaceutical
Commercial-stage rare disease biopharma developing therapies for serious genetic disorders.
Yes, Cortexyme is publicly traded under the ticker symbol CRTX on the NASDAQ. The company went public in May 9, 2019.
Cortexyme trades under the ticker symbol CRTX on the NASDAQ. It began trading in May 9, 2019.
Cortexyme (CRTX on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker CRTX to place an order.
Cortexyme went public in May 9, 2019 via ipo. Cortexyme listed on Nasdaq as CRTX in May 2019 at $17.00 per share and was renamed Quince Therapeutics (QNCX) in August 2022. After acquiring Orphai Therapeutics in May 2026, it called a special stockholder meeting for October 6, 2026; if the proposals are approved, it expects to rename itself IRulya Therapeutics and trade on the Nasdaq Capital Market as IRLA.
Cortexyme raised $101.7M across 2 disclosed funding rounds prior to its public listing.
Cortexyme is headquartered in South San Francisco, CA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.